脓毒症抗凝治疗的意义与未来
脓毒症时凝血系统激活、抗凝机制受抑,微血栓形成并可发生弥散性血管内凝血。尽管抗凝治疗存在争议,但适当抗凝可有效降低脓毒性弥散性血管内凝血、脓毒性休克和高危人群的死亡率,并减少多器官功能障碍综合征的发生。脓毒症诱导的凝血功能障碍(SIC)评分基于国际血栓与止血学会(ISTH)显性弥散性血管内凝血评分和Sepsis-3优化,可敏感监测凝血功能障碍。SIC评分≥4分是启动抗凝治疗的最佳时机,国际推荐抗凝血酶、血栓调节蛋白、组织因子途径抑制物、肝素等,国内推荐普通肝素和低分子肝素。
要点
- 脓毒症诱导的凝血功能障碍(SIC)评分≥4分是启动抗凝治疗的最佳时机。
- SIC评分基于国际血栓与止血学会(ISTH)显性弥散性血管内凝血评分和Sepsis-3优化,包括血小板、国际标准化比值(INR)和序贯器官衰竭评估(SOFA)。
- 适当抗凝可有效降低脓毒性弥散性血管内凝血、脓毒性休克和高危人群的死亡率,并减少多器官功能障碍综合征的发生。
- 国内推荐的抗凝药物仅为普通肝素和低分子肝素;国际推荐还包括抗凝血酶、血栓调节蛋白、组织因子途径抑制物等。
- 使用抗凝药物前需评估出血和血栓风险,并注意患者原发病;无明显抗凝禁忌时,尽量采用从普通肝素过渡到低分子肝素的治疗策略。
适用人群与场景
- 脓毒症患者,尤其是脓毒性弥散性血管内凝血、脓毒性休克和高危人群。
诊断标准与关键阈值
- 脓毒症诱导的凝血功能障碍(SIC)评分≥4分是启动抗凝治疗的最佳时机。
- SIC评分基于国际血栓与止血学会(ISTH)显性弥散性血管内凝血评分和Sepsis-3优化,包括血小板、国际标准化比值(INR)和序贯器官衰竭评估(SOFA)。
处置流程与药物剂量
- 使用抗凝药物前,需评估患者出血和血栓的可能性。
- 同时需注意患者原发病。
- 无明显抗凝禁忌时,尽量采用从普通肝素过渡到低分子肝素的治疗策略。
- 国内推荐的抗凝药物为普通肝素和低分子肝素。
- 国际推荐的抗凝药物包括抗凝血酶(AT)、血栓调节蛋白(TM)、组织因子途径抑制物(TFPI)、肝素等。
研究设计与关键结果
- 脓毒症时凝血系统激活导致高凝状态,抗凝机制显著受抑,大量微血栓形成,可发生弥散性血管内凝血(DIC)。
- 适当抗凝可有效降低脓毒性弥散性血管内凝血、脓毒性休克和高危人群的死亡率,并最终有效减少多器官功能障碍综合征的发生。
- SIC评分可敏感监测脓毒症诱导的凝血功能障碍。
证据类型、等级与局限
- 证据类型:综述。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对脓毒症患者应使用SIC评分监测凝血功能障碍,评分≥4分时启动抗凝治疗。
- 启动抗凝前需评估出血和血栓风险,并关注原发病。
- 国内可选抗凝药物为普通肝素和低分子肝素;无明显抗凝禁忌时,尽量采用从普通肝素过渡到低分子肝素的策略。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Sepsis is caused by the imbalance of the host body's response to infection, which causes life-threatening organ dysfunction. Disorders of blood coagulation play a very important role in the development of sepsis. In sepsis, the body's coagulation system is activated, leading to hypercoagulability, while the anticoagulation mechanism is significantly inhibited, causing a large number of microthrombi to form, and disseminated intravascular coagulation (DIC) may occur. Although there are obvious controversies about the anticoagulation treatment of sepsis at home and abroad, we cannot deny the significance of anticoagulation treatment in sepsis. Only appropriate anticoagulation can effectively reduce the mortality in septic DIC, septic shock and high-risk population, and ultimately effectively reduce the occurrence of multiple organ dysfunction syndrome. The sepsis-induced coagulation dysfunction (SIC) score is currently used internationally to guide anticoagulation. SIC score is optimized based on the International Society on Thrombosis and Haemostasis (ISTH) overt DIC score and Sepsis-3, including platelet, international normalized ratio (INR) and sequential organ failure assessment (SOFA). The SIC score can sensitively monitor sepsis-induced coagulation dysfunction. When the SIC score is ≥ 4, it is the best timing to initiate anticoagulation therapy. At present, the internationally recommended anticoagulant drugs include antithrombin (AT), thrombomodulin (TM), tissue factor pathway inhibitor (TFPI), heparin, etc., while the domestically recommended anticoagulant drugs are only unfractionated heparin and low molecular weight heparin. Before using anticoagulant drugs, it is necessary to evaluate the possibility of bleeding and thrombosis in the patients. At the same time, it is necessary to pay attention to the patient's primary disease. Try to adopt the treatment strategy of transitioning from unfractionated heparin to low molecular weight heparin without obvious anticoagulation contraindications.
参考来源
- Xu W, Li M, Cui G, et al. [Significance and future of anticoagulant therapy for sepsis]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2021. PMID: 34112306. doi:10.3760/cma.j.cn121430-20201126-00731
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。